Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial

Prospective data from phase 1

Jonathan M. Meyer, Vicki G. Davis, Donald C. Goff, Joseph Patrick McEvoy, Henry A. Nasrallah, Sonia M. Davis, Robert A. Rosenheck, Gail L. Daumit, John Hsiao, Marvin S. Swartz, T. Scott Stroup, Jeffrey A. Lieberman

Research output: Contribution to journalArticle

203 Citations (Scopus)

Abstract

Background: The metabolic syndrome (MS) is associated with increased risk for diabetes mellitus and coronary heart disease, and is highly prevalent among schizophrenia patients. Given concerns over antipsychotic metabolic effects, this analysis explored MS status and outcomes in phase 1 of the CATIE Schizophrenia Trial. Methods: The change in proportion of subjects with MS and individual criteria was compared between antipsychotic treatment groups, along with mean changes for individual criteria. Primary analyses examined subjects with fasting laboratory assessments at baseline and 3 months. Other analyses examined 3-month changes in MS status, waist circumference (WC), HDL cholesterol and blood pressure in all subjects, metabolic changes at the end of phase 1 participation (EOP), and repeated measures changes in HDL, blood pressure (BP) and WC over phase 1. Results: At 3 months, there were no significant between-drug differences for the change in proportion of subjects meeting MS status or individual MS criteria in the smaller fasting cohort (n = 281) or for those meeting criteria for parameters not dependent on fasting status (BP, HDL, WC) among all subjects (n = 660). Among all subjects whose MS status could be determined at 3 months (n = 660), MS prevalence increased for olanzapine (from 34.8% to 43.9%), but decreased for ziprasidone (from 37.7% to 29.9%) (p = .001). Although effect sizes varied across subgroups, at 3 months olanzapine and quetiapine had the largest mean increase in waist circumference (0.7 in. for both) followed by risperidone (0.4 in.), compared to no change for ziprasidone (0.0 in.) and a decrease in waist circumference for perphenazine (- 0.4 in.). Olanzapine also demonstrated significantly different changes in fasting triglycerides at 3 months (+ 21.5 mg/dl) compared to ziprasidone (- 32.1 mg/dl). EOP exposure data was obtained, on average, nine months from baseline for all metabolic variables. Results from EOP and repeated measures analyses were consistent with those at 3 months for mean changes in WC and fasting triglycerides, but between group differences emerged for HDL and SBP. Conclusions: This large non-industry sponsored study confirms the differential metabolic effects between antipsychotics. Clinicians are advised to monitor all metabolic parameters, including WC, HDL and serum triglycerides, during antipsychotic treatment.

Original languageEnglish (US)
Pages (from-to)273-286
Number of pages14
JournalSchizophrenia Research
Volume101
Issue number1-3
DOIs
StatePublished - Apr 1 2008

Fingerprint

Waist Circumference
Antipsychotic Agents
Schizophrenia
olanzapine
Fasting
Triglycerides
Therapeutics
Blood Pressure
Perphenazine
Risperidone
HDL Cholesterol
Coronary Disease
Diabetes Mellitus
Serum
Pharmaceutical Preparations
ziprasidone

Keywords

  • Antipsychotic
  • Central adiposity
  • HDL
  • Lipids
  • Metabolic syndrome
  • Schizophrenia
  • Triglycerides
  • Waist circumference

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial : Prospective data from phase 1. / Meyer, Jonathan M.; Davis, Vicki G.; Goff, Donald C.; McEvoy, Joseph Patrick; Nasrallah, Henry A.; Davis, Sonia M.; Rosenheck, Robert A.; Daumit, Gail L.; Hsiao, John; Swartz, Marvin S.; Stroup, T. Scott; Lieberman, Jeffrey A.

In: Schizophrenia Research, Vol. 101, No. 1-3, 01.04.2008, p. 273-286.

Research output: Contribution to journalArticle

Meyer, JM, Davis, VG, Goff, DC, McEvoy, JP, Nasrallah, HA, Davis, SM, Rosenheck, RA, Daumit, GL, Hsiao, J, Swartz, MS, Stroup, TS & Lieberman, JA 2008, 'Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1', Schizophrenia Research, vol. 101, no. 1-3, pp. 273-286. https://doi.org/10.1016/j.schres.2007.12.487
Meyer, Jonathan M. ; Davis, Vicki G. ; Goff, Donald C. ; McEvoy, Joseph Patrick ; Nasrallah, Henry A. ; Davis, Sonia M. ; Rosenheck, Robert A. ; Daumit, Gail L. ; Hsiao, John ; Swartz, Marvin S. ; Stroup, T. Scott ; Lieberman, Jeffrey A. / Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial : Prospective data from phase 1. In: Schizophrenia Research. 2008 ; Vol. 101, No. 1-3. pp. 273-286.
@article{771cdbe56d0648f4aa4d7d15ab5e29da,
title = "Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1",
abstract = "Background: The metabolic syndrome (MS) is associated with increased risk for diabetes mellitus and coronary heart disease, and is highly prevalent among schizophrenia patients. Given concerns over antipsychotic metabolic effects, this analysis explored MS status and outcomes in phase 1 of the CATIE Schizophrenia Trial. Methods: The change in proportion of subjects with MS and individual criteria was compared between antipsychotic treatment groups, along with mean changes for individual criteria. Primary analyses examined subjects with fasting laboratory assessments at baseline and 3 months. Other analyses examined 3-month changes in MS status, waist circumference (WC), HDL cholesterol and blood pressure in all subjects, metabolic changes at the end of phase 1 participation (EOP), and repeated measures changes in HDL, blood pressure (BP) and WC over phase 1. Results: At 3 months, there were no significant between-drug differences for the change in proportion of subjects meeting MS status or individual MS criteria in the smaller fasting cohort (n = 281) or for those meeting criteria for parameters not dependent on fasting status (BP, HDL, WC) among all subjects (n = 660). Among all subjects whose MS status could be determined at 3 months (n = 660), MS prevalence increased for olanzapine (from 34.8{\%} to 43.9{\%}), but decreased for ziprasidone (from 37.7{\%} to 29.9{\%}) (p = .001). Although effect sizes varied across subgroups, at 3 months olanzapine and quetiapine had the largest mean increase in waist circumference (0.7 in. for both) followed by risperidone (0.4 in.), compared to no change for ziprasidone (0.0 in.) and a decrease in waist circumference for perphenazine (- 0.4 in.). Olanzapine also demonstrated significantly different changes in fasting triglycerides at 3 months (+ 21.5 mg/dl) compared to ziprasidone (- 32.1 mg/dl). EOP exposure data was obtained, on average, nine months from baseline for all metabolic variables. Results from EOP and repeated measures analyses were consistent with those at 3 months for mean changes in WC and fasting triglycerides, but between group differences emerged for HDL and SBP. Conclusions: This large non-industry sponsored study confirms the differential metabolic effects between antipsychotics. Clinicians are advised to monitor all metabolic parameters, including WC, HDL and serum triglycerides, during antipsychotic treatment.",
keywords = "Antipsychotic, Central adiposity, HDL, Lipids, Metabolic syndrome, Schizophrenia, Triglycerides, Waist circumference",
author = "Meyer, {Jonathan M.} and Davis, {Vicki G.} and Goff, {Donald C.} and McEvoy, {Joseph Patrick} and Nasrallah, {Henry A.} and Davis, {Sonia M.} and Rosenheck, {Robert A.} and Daumit, {Gail L.} and John Hsiao and Swartz, {Marvin S.} and Stroup, {T. Scott} and Lieberman, {Jeffrey A.}",
year = "2008",
month = "4",
day = "1",
doi = "10.1016/j.schres.2007.12.487",
language = "English (US)",
volume = "101",
pages = "273--286",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial

T2 - Prospective data from phase 1

AU - Meyer, Jonathan M.

AU - Davis, Vicki G.

AU - Goff, Donald C.

AU - McEvoy, Joseph Patrick

AU - Nasrallah, Henry A.

AU - Davis, Sonia M.

AU - Rosenheck, Robert A.

AU - Daumit, Gail L.

AU - Hsiao, John

AU - Swartz, Marvin S.

AU - Stroup, T. Scott

AU - Lieberman, Jeffrey A.

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Background: The metabolic syndrome (MS) is associated with increased risk for diabetes mellitus and coronary heart disease, and is highly prevalent among schizophrenia patients. Given concerns over antipsychotic metabolic effects, this analysis explored MS status and outcomes in phase 1 of the CATIE Schizophrenia Trial. Methods: The change in proportion of subjects with MS and individual criteria was compared between antipsychotic treatment groups, along with mean changes for individual criteria. Primary analyses examined subjects with fasting laboratory assessments at baseline and 3 months. Other analyses examined 3-month changes in MS status, waist circumference (WC), HDL cholesterol and blood pressure in all subjects, metabolic changes at the end of phase 1 participation (EOP), and repeated measures changes in HDL, blood pressure (BP) and WC over phase 1. Results: At 3 months, there were no significant between-drug differences for the change in proportion of subjects meeting MS status or individual MS criteria in the smaller fasting cohort (n = 281) or for those meeting criteria for parameters not dependent on fasting status (BP, HDL, WC) among all subjects (n = 660). Among all subjects whose MS status could be determined at 3 months (n = 660), MS prevalence increased for olanzapine (from 34.8% to 43.9%), but decreased for ziprasidone (from 37.7% to 29.9%) (p = .001). Although effect sizes varied across subgroups, at 3 months olanzapine and quetiapine had the largest mean increase in waist circumference (0.7 in. for both) followed by risperidone (0.4 in.), compared to no change for ziprasidone (0.0 in.) and a decrease in waist circumference for perphenazine (- 0.4 in.). Olanzapine also demonstrated significantly different changes in fasting triglycerides at 3 months (+ 21.5 mg/dl) compared to ziprasidone (- 32.1 mg/dl). EOP exposure data was obtained, on average, nine months from baseline for all metabolic variables. Results from EOP and repeated measures analyses were consistent with those at 3 months for mean changes in WC and fasting triglycerides, but between group differences emerged for HDL and SBP. Conclusions: This large non-industry sponsored study confirms the differential metabolic effects between antipsychotics. Clinicians are advised to monitor all metabolic parameters, including WC, HDL and serum triglycerides, during antipsychotic treatment.

AB - Background: The metabolic syndrome (MS) is associated with increased risk for diabetes mellitus and coronary heart disease, and is highly prevalent among schizophrenia patients. Given concerns over antipsychotic metabolic effects, this analysis explored MS status and outcomes in phase 1 of the CATIE Schizophrenia Trial. Methods: The change in proportion of subjects with MS and individual criteria was compared between antipsychotic treatment groups, along with mean changes for individual criteria. Primary analyses examined subjects with fasting laboratory assessments at baseline and 3 months. Other analyses examined 3-month changes in MS status, waist circumference (WC), HDL cholesterol and blood pressure in all subjects, metabolic changes at the end of phase 1 participation (EOP), and repeated measures changes in HDL, blood pressure (BP) and WC over phase 1. Results: At 3 months, there were no significant between-drug differences for the change in proportion of subjects meeting MS status or individual MS criteria in the smaller fasting cohort (n = 281) or for those meeting criteria for parameters not dependent on fasting status (BP, HDL, WC) among all subjects (n = 660). Among all subjects whose MS status could be determined at 3 months (n = 660), MS prevalence increased for olanzapine (from 34.8% to 43.9%), but decreased for ziprasidone (from 37.7% to 29.9%) (p = .001). Although effect sizes varied across subgroups, at 3 months olanzapine and quetiapine had the largest mean increase in waist circumference (0.7 in. for both) followed by risperidone (0.4 in.), compared to no change for ziprasidone (0.0 in.) and a decrease in waist circumference for perphenazine (- 0.4 in.). Olanzapine also demonstrated significantly different changes in fasting triglycerides at 3 months (+ 21.5 mg/dl) compared to ziprasidone (- 32.1 mg/dl). EOP exposure data was obtained, on average, nine months from baseline for all metabolic variables. Results from EOP and repeated measures analyses were consistent with those at 3 months for mean changes in WC and fasting triglycerides, but between group differences emerged for HDL and SBP. Conclusions: This large non-industry sponsored study confirms the differential metabolic effects between antipsychotics. Clinicians are advised to monitor all metabolic parameters, including WC, HDL and serum triglycerides, during antipsychotic treatment.

KW - Antipsychotic

KW - Central adiposity

KW - HDL

KW - Lipids

KW - Metabolic syndrome

KW - Schizophrenia

KW - Triglycerides

KW - Waist circumference

UR - http://www.scopus.com/inward/record.url?scp=43049092201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049092201&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2007.12.487

DO - 10.1016/j.schres.2007.12.487

M3 - Article

VL - 101

SP - 273

EP - 286

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -